Tofacitinib is not a biologic
نویسندگان
چکیده
منابع مشابه
Tofacitinib is not a biologic
As the Global Medical Affairs Gastroenterology Lead for tofacitinib at Pfizer, I read with great interest the review by Dr Ungar and Dr Kopylov entitled “Advances in the development of new biologics in inflammatory bowel disease (IBD)” [1]. In reading the article, I identified a number of inaccuracies concerning tofacitinib, which I thought should be brought to the attention of the authors and ...
متن کاملTofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients
Objective This study was designed to directly compare the outcomes of tofacitinib therapy for methotrexate-refractory rheumatoid arthritis (RA) between biologic-naïve patients and patients who had experienced an inadequate response to biological agents. Methods We prospectively enrolled and followed 113 patients who had a high or moderate clinical disease activity index (CDAI) (36 biologic-naïv...
متن کاملTofacitinib
Tofacitinib (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant, is being developed by Pfizer for the treatment of rheumatoid arthritis, inflammatory bowel disease, dry eyes, ankylosing spondylitis, psoriasis, psoriatic arthritis, and for the prevention of transplant rejection. Tofacitinib specifically inhibits Janus activated kinase 3 (JAK3), which has a pivotal role in cytok...
متن کاملStroke in MELAS is a Vasogenic Edema and Not Ischemic
We read with interest the article by Almasi et al. on a 48 years old female patient with Mitochondrial Encephalomyopathy, Lactic Acidosis, And Stroke-like episodes (MELAS), diagnosed based on the clinical presentation, blood test results, and imaging and muscle biopsy findings . We have the following comments and concerns.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Gastroenterology
سال: 2016
ISSN: 1792-7463
DOI: 10.20524/aog.2016.0094